Proactiveinvestors Australia Allergy Therapeutics PLC https://www.proactiveinvestors.com.au Proactiveinvestors Australia Allergy Therapeutics PLC RSS feed en Mon, 22 Jul 2019 01:02:42 +1000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Trading update ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190711070006_14144280/ Thu, 11 Jul 2019 16:00:06 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190711070006_14144280/ <![CDATA[RNS press release - Successful Litigation Settlement ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190627070015_14126227/ Thu, 27 Jun 2019 16:00:15 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190627070015_14126227/ <![CDATA[RNS press release - Trading Statement ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190627070009_14126945/ Thu, 27 Jun 2019 16:00:09 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190627070009_14126945/ <![CDATA[RNS press release - Board Change ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190619070004_14115867/ Wed, 19 Jun 2019 16:00:04 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190619070004_14115867/ <![CDATA[RNS press release - Holdings in Company ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190611070009_14105707/ Tue, 11 Jun 2019 16:00:09 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190611070009_14105707/ <![CDATA[RNS press release - Positive top line phase I results for Acarovac MPL ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190520070020_14079322/ Mon, 20 May 2019 16:00:20 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190520070020_14079322/ <![CDATA[RNS press release - Holdings in Company ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190514070011_14072447/ Tue, 14 May 2019 16:00:11 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190514070011_14072447/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190513181414_14072257/ Tue, 14 May 2019 03:14:14 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190513181414_14072257/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190513164118_14072117/ Tue, 14 May 2019 01:41:18 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190513164118_14072117/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190513163550_14072104/ Tue, 14 May 2019 01:35:50 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190513163550_14072104/ <![CDATA[RNS press release - Research Published on Adjuvant Systems ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190507070009_14063816/ Tue, 07 May 2019 16:00:09 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190507070009_14063816/ <![CDATA[RNS press release - Regulatory and Trading Update ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190425070007_14051004/ Thu, 25 Apr 2019 16:00:07 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190425070007_14051004/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318164125_14006349/ Tue, 19 Mar 2019 03:41:25 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318164125_14006349/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318163606_14006338/ Tue, 19 Mar 2019 03:36:06 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318163606_14006338/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318110524_14005832/ Mon, 18 Mar 2019 22:05:24 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318110524_14005832/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318110029_14005826/ Mon, 18 Mar 2019 22:00:29 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318110029_14005826/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318090531_14005619/ Mon, 18 Mar 2019 20:05:31 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318090531_14005619/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318090033_14005612/ Mon, 18 Mar 2019 20:00:33 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318090033_14005612/ <![CDATA[RNS press release - Top Line Phase III results from B301 trial ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318070006_14004999/ Mon, 18 Mar 2019 18:00:06 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190318070006_14004999/ <![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190306070005_13991474/ Wed, 06 Mar 2019 18:00:05 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190306070005_13991474/ <![CDATA[RNS press release - Trading Update & Notice of Results ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190116070003_13935895/ Wed, 16 Jan 2019 18:00:03 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20190116070003_13935895/ <![CDATA[RNS press release - Holdings in Company ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181129175923_13885935/ Fri, 30 Nov 2018 04:59:23 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181129175923_13885935/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181127131215_13882224/ Wed, 28 Nov 2018 00:12:15 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181127131215_13882224/ <![CDATA[RNS press release - AGM Trading Update ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181127070014_13881051/ Tue, 27 Nov 2018 18:00:14 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181127070014_13881051/ <![CDATA[RNS press release - Presentation at Jefferies Healthcare Conference ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181112120004_13863557/ Mon, 12 Nov 2018 23:00:04 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181112120004_13863557/ <![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181108070016_13859327/ Thu, 08 Nov 2018 18:00:16 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181108070016_13859327/ <![CDATA[RNS press release - Holdings in Company ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181107180655_13859110/ Thu, 08 Nov 2018 05:06:55 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181107180655_13859110/ <![CDATA[RNS press release - Grant of Awards under Long Term Incentive Plan ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181102070003_13852422/ Fri, 02 Nov 2018 18:00:03 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181102070003_13852422/ <![CDATA[RNS press release - Holdings in Company ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181024132550_13840978/ Wed, 24 Oct 2018 23:25:50 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181024132550_13840978/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181024070003_13839884/ Wed, 24 Oct 2018 17:00:03 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181024070003_13839884/ <![CDATA[RNS press release - Annual Report and Accounts ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181023172926_13839683/ Wed, 24 Oct 2018 03:29:26 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181023172926_13839683/ <![CDATA[RNS press release - Holdings in Company ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181023152835_13839567/ Wed, 24 Oct 2018 01:28:35 +1100 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20181023152835_13839567/ <![CDATA[RNS press release - Preliminary Results ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180926070004_13804539/ Wed, 26 Sep 2018 16:00:04 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180926070004_13804539/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180808070005_13747374/ Wed, 08 Aug 2018 16:00:05 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180808070005_13747374/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180727172606_13734932/ Sat, 28 Jul 2018 02:26:06 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180727172606_13734932/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180726120244_13732861/ Thu, 26 Jul 2018 21:02:44 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180726120244_13732861/ <![CDATA[RNS press release - Results of Placing and Subscription ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180719101920_13724136/ Thu, 19 Jul 2018 19:19:20 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180719101920_13724136/ <![CDATA[RNS press release - Proposed placing & subscription to raise £10.6m ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180719070005_13723349/ Thu, 19 Jul 2018 16:00:05 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180719070005_13723349/ <![CDATA[News - Allergy Therapeutics raises £10.6mln to fund expansion of late-stage PQ Grass study ]]> https://www.proactiveinvestors.com.au/companies/news/201111/allergy-therapeutics-raises-106mln-to-fund-expansion-of-late-stage-pq-grass-study-201111.html Allergy Therapeutics plc (LON:AGY) has raised £10.6mln to fund the expansion of the phase III clinical trial of its grass pollen-induced hay fever immunotherapy.

The AIM-quoted firm placed 40mln new shares at 26.5p each – slightly below yesterday’s closing price of 28p.

READ: AGY full-year revenues to rise despite weak pollen season

“Allergy Therapeutics is poised for a transformational period of growth both with our marketed products and our R&D pipeline,” said chief executive Manuel Llobet.

“With this successful placing and subscription, we will expand our planned phase III PQ Grass trial, scheduled to start in H2 2019, including a project to analyse pollen trends in the US to maximise the exposure of patients to grass pollen.

“We will also support the Acarovac phase II trial and, looking further out, further progress our diversified pipeline of patient-friendly, convenient to use products including Polyvac Peanut.”

Earlier this year, Allergy hailed the “extremely positive results” from the phase II trial of PQ Grass, with those taking the drug showing “a highly statistically significant” reduction in symptoms compared to patients in the placebo arm of the study.

READ: AGY readies PQ Grass for phase III trial

Allergy already has a treatment for grass pollen-induced allergic rhinitis – a fancy term for hay fever. But this new formulation is an injection which includes an adjuvant to help boost the body’s immune response.

One of the key target markets for PQ Grass is the US, where it would be the first immunotherapy injection to be registered and where peak grass vaccine sales could be US$300-$400mln a year.

As well as funding the late-stage PQ Grass trial, the cash will also be used to part-fund the phase II study of Acarovac, the company’s dust mite allergy treatment.

Allergy share dipped 2.5% to 27p on Thursday morning.

--Updates for completion of placing, share price--

]]>
Thu, 19 Jul 2018 07:35:00 +1000 https://www.proactiveinvestors.com.au/companies/news/201111/allergy-therapeutics-raises-106mln-to-fund-expansion-of-late-stage-pq-grass-study-201111.html
<![CDATA[RNS press release - BLOCK LISTING SIX MONTHLY RETURN ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180716085303_13718813/ Mon, 16 Jul 2018 17:53:03 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180716085303_13718813/ <![CDATA[RNS press release - Trading Update ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180712070005_13714746/ Thu, 12 Jul 2018 16:00:05 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180712070005_13714746/ <![CDATA[News - Allergy Therapeutics full-year revenues to rise once again despite “unusually weak” pollen season ]]> https://www.proactiveinvestors.com.au/companies/news/200649/allergy-therapeutics-full-year-revenues-to-rise-once-again-despite-unusually-weak-pollen-season-200649.html Allergy Therapeutics plc (LON:AGY) expects its top-line to jump once again this year, despite an “unusually weak” pollen season.

As the name suggests, the AIM-quoted firm makes vaccines which are used to treat pollen-related allergies, particularly allergies to grasses and trees.

READ: AGY readies grass pollen treatment for phase III trial

In a year-end trading update, Allergy told investors that revenue for the 12 months to June 30 should grow 6.6% to £68.3mln (2017: £64.1mln), in-line with current expectations.

The cash balance at the end of June was £15.5mln (June 30 2017: £22.1mln).

Allergy added that it has continued to gain market share within its core markets with data for the nine months through to the end of March showing an increase of 0.7 of a market share point.

As for pipeline, that continues to “progress well”. The company is readying its latest grass pollen-induced hay fever immunotherapy for phase III trials after announcing “extremely positive” results from a -mid-stage study back in May.

‘Strong performance’

Results from a phase III trial of its birch pollen vaccine are due in the current quarter (Q3 2018) as well.

“Our convenient, flexible and varied product portfolio has enabled us over the past 19 years to grow revenues at 10% compound annual growth rate,” said chief executive Manuel Llobet.

“We are pleased that we have continued to make headway in market share this year, despite a poor pollen season, and have maintained a tight control on costs in the period.”

He added: “Our pipeline continues to progress well, with the announcement of excellent Grass phase II results, the publication of significant papers on the long-term effect of our product and the positive Birch phase II trials.”

]]>
Thu, 12 Jul 2018 07:41:00 +1000 https://www.proactiveinvestors.com.au/companies/news/200649/allergy-therapeutics-full-year-revenues-to-rise-once-again-despite-unusually-weak-pollen-season-200649.html
<![CDATA[RNS press release - Positive data of Pollinex Quattro Grass vaccine ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180625075228_13691732/ Mon, 25 Jun 2018 16:52:28 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180625075228_13691732/ <![CDATA[News - Allergy Therapeutics announces publication of positive data of Pollinex Quattro Grass vaccines ]]> https://www.proactiveinvestors.com.au/companies/news/199455/allergy-therapeutics-announces-publication-of-positive-data-of-pollinex-quattro-grass-vaccines-199455.html Allergy Therapeutics plc (LON:AGY) has announced the publication of positive data in the journal Immunotherapy, demonstrating the long-lasting efficacy of Pollinex Quattro grass in patients with grass pollen allergy.

The AIM-listed firm said the observational study, led by Professor Stefan Zielen of the Goethe University, Germany, focused on the long-term efficacy of Pollinex Quattro Grass. 

READ: Allergy Therapeutics announces positive new clinic data with house-dust mite immunotherapy

The company, specialising in allergy vaccines, said each of the clinical symptoms (runny nose, sneezing and conjunctivitis) were statistically significantly reduced in treated patients compared with controls without allergen-specific immunotherapy.

Allergy Therapeutics said the study concluded that patients treated with Pollinex Quattro Grass vaccine exhibited significant and long-lasting symptom improvements 3-6 years after cessation of treatment.

Manuel Llobet, CEO at Allergy Therapeutics, said: ”Together with the recently announced positive data from our Phase Grass G205 clinical study, we believe that we have a robust data set for our suite of novel allergy product candidates.”

He added: “We look forward to commencing further studies with the goal of developing a strong allergy portfolio to patients globally, including in the significant US market."

]]>
Mon, 25 Jun 2018 07:31:00 +1000 https://www.proactiveinvestors.com.au/companies/news/199455/allergy-therapeutics-announces-publication-of-positive-data-of-pollinex-quattro-grass-vaccines-199455.html
<![CDATA[RNS press release - Positive data with house-dust mite immunotherapy ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180529070016_13657117/ Tue, 29 May 2018 16:00:16 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180529070016_13657117/ <![CDATA[News - Allergy Therapeutics announces positive new clinic data with house-dust mite immunotherapy ]]> https://www.proactiveinvestors.com.au/companies/news/197788/allergy-therapeutics-announces-positive-new-clinic-data-with-house-dust-mite-immunotherapy-197788.html Allergy Therapeutics PLC (LON:AGY) said that house-dust immunotherapy has shown to be well-tolerated and demonstrates highly significant symptom improvement.

The AIM-listed biotechnology company said at the 37 Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Munich, Germany, that this observational study was conducted in ten sites across Spain. The total 141 patients were evaluated and they demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year. 

READ: Allergy Therapeutics highlights benefits of adjuvant technology in new paper

In addition, in a subgroup of asthmatic subjects, 16.7% of patients were observed with moderate persistent asthma at one year compared with 50.9% at baseline.

The company, specialising in allergy vaccines, said its modified house-dust mite product sold as through a Named Patient Program in Spain, is the precursor to the modified house-dust mite + MPL product currently in Phase I.

Allergy Therapeutics said it presented a series of poster presentations at EAACI with key highlights and held a satellite symposium which provided a summary of how adjuvant technologies have evolved.

Manuel Llobet, chief executive officer, said in a statement: “The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our Grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength.”

He added: “And we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products."

]]>
Tue, 29 May 2018 07:32:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197788/allergy-therapeutics-announces-positive-new-clinic-data-with-house-dust-mite-immunotherapy-197788.html
<![CDATA[RNS press release - Positive top-line results from Grass Ph II study ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180521070010_13647876/ Mon, 21 May 2018 16:00:10 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180521070010_13647876/ <![CDATA[Media files - Allergy Therapeutics on track for phase III grass pollen trial in 2019 ]]> https://www.proactiveinvestors.com.au/companies/stocktube/9336/allergy-therapeutics-on-track-for-phase-iii-grass-pollen-trial-in-2019-9336.html Mon, 21 May 2018 08:59:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/9336/allergy-therapeutics-on-track-for-phase-iii-grass-pollen-trial-in-2019-9336.html <![CDATA[News - Allergy Therapeutics readies grass pollen treatment for Phase III trial after “extremely positive” mid-stage results ]]> https://www.proactiveinvestors.com.au/companies/news/197344/allergy-therapeutics-readies-grass-pollen-treatment-for-phase-iii-trial-after-extremely-positive-mid-stage-results-197344.html Allergy Therapeutics PLC (LON:AGY) has hailed the “extremely positive results” from the Phase II trial of its grass pollen-induced hay fever immunotherapy.

The AIM-quoted firm said PQ Grass met its primary endpoint, with those taking the drug showing “a highly statistically significant” reduction in symptoms compared to patients in the placebo arm of the study.

READ: Allergy Thera highlights benefits of adjuvant technology WATCH: CEO upbeat after latest trial results

Allergy already has a treatment for grass pollen-induced allergic rhinitis – a fancy term for hay fever. But this new formulation is an injection which includes an adjuvant to help boost the body’s immune response.

“We are thrilled with these extremely positive results demonstrating dose-dependent efficacy of the product including the current marketed dose,” said chief executive Manuel Llobet.

“With an optimal dose identified, we look forward to sharing this new, exciting data with the health authorities and plan to commence a phase III study in 2019.”

One of the key target markets for the PQ Grass is the US, where it would be the first immunotherapy injection to be registered and where peak grass vaccine sales could be US$300-$400mln a year.

Doctors want injectable treatments

“Allergy is the only company to have been putting material investment into more convenient injections, that are preferred by physicians in the largest markets in the world (Germany, US, Japan),” wrote Numis analyst Paul Cuddon in a research note.

“We expect this to pay dividends longer term given the improved patient adherence and clinical results with SCIT (injection) over SLIT (under-the-tongue), and the likelihood that a large number of competitor products will be taken off the market given the heightened standards.” 

Cuddon has the stock as ‘buy’ with a 45p target price. Allergy shares rose 8.1% to 26.5p in early deals on Monday.

The company has three growth ‘pillars’, which includes growing strongly in its European heartland where it has a robust, profitable business.

Three pillars

It wants to do this by expanding its market share and making additional product registrations.

It has a strong pipeline of products coming through and investment in this regard will help underpin the bedrock of the business. This is growth pillar two.

The third is the US, which as the largest allergy market in the world, provides a significant opportunity. The environment there is changing, potentially driving new customers towards the firm’s products.

As mentioned above, the potential market size of the US could be transformational for Allergy Therapeutics as the graphic below reveals.

Allergy Therapeutics has an 80-year history and so is no “jam tomorrow” drug development company and was spun out of SmithKline Beecham in 1999.

No flash in the pan

Headquartered in Worthing, West Sussex, it employs around 500 people.

Its most commonly prescribed vaccines are used to treat pollen-related allergies, particularly allergies to grasses and trees.

It has a strong presence in Europe, with established operations in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the United Kingdom, while in other markets, it often makes its products available through distribution partners.

Its Pollinex Quattro vaccine for the treatment of seasonal allergic rhinitis (hay fever) from grass, tree or ragweed pollen allergy is already established in Europe.

-- adds background information --

]]>
Mon, 21 May 2018 07:39:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197344/allergy-therapeutics-readies-grass-pollen-treatment-for-phase-iii-trial-after-extremely-positive-mid-stage-results-197344.html
<![CDATA[RNS press release - Publication of MCT Adjuvant Data ]]> https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180514070011_13639034/ Mon, 14 May 2018 16:00:11 +1000 https://www.proactiveinvestors.com.au/companies/rns/43/LSE20180514070011_13639034/